UOC
ESPR

UBS O'Connor’s Esperion Therapeutics ESPR Stock Holding History

UBS O'Connor’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-125,000
Closed -$158K – 657
2022
Q4 		$158K Buy
+125,000
New +$894K ﹤0.01% 656

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS O'Connor's ESPR Position: Q2 2024 in Review

UBS O'Connor sold out of Esperion Therapeutics (ESPR) in Q2 2024, closing a stake of 142,418 shares — an estimated $382K sold.

UBS O'Connor first reported a position in ESPR in Q3 2022 and held it in 7 quarters. The position peaked at $1.58M in Q4 2023. 176 funds tracked by Wall St. Rank hold ESPR as of Q2 2024.

  • UBS O'Connor reported no remaining Esperion Therapeutics position as of Q2 2024 after selling out during the quarter.
  • UBS O'Connor sold 142,418 Esperion Therapeutics shares in Q2 2024, an estimated $382K.
  • UBS O'Connor first reported a position in Esperion Therapeutics in Q3 2022 and held it in 7 quarters.
  • UBS O'Connor's Esperion Therapeutics position peaked at $1.58M in Q4 2023.
  • 176 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2024.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.